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Background: The Tigecycline In-Vitro Surveillance in Tai-
wan (TIST), initiated in 2006, is a nationwide surveillance
program designed to monitor longitudinally the in vitro
activities of tigecycline against commonly encountered
resistant bacteria in Taiwan. This study aims to compare the
in vitro activities of tigecycline against clinical isolates of
Acinetobacter baumannii by using two susceptibility meth-
ods.
Methods: A total of 393 isolates of A. baumannii were
collected from various sources of patients treated at
20 teaching hospitals. Minimum inhibitory concentrations
(MICs) and diameters of inhibitory zone for tigecycline
were determined by the broth microdilution methods and
the disk diffusion method, respectively. The results were
interpreted by the MIC criteria provided by U.S. FDA
tigecycline susceptibility breakpoints listed for Enterobac-
teriaceae (S, ≤2g/mL; I, 4g/mL; R, ≥8g/mL) and by
the disk diffusion breakpoints (S, ≤16mm; I, 13—15mm;
R, ≥12mm) recommended by Jones et al (J. Clin. Micro-
biol 2007;45:227—30). A very major error (VME) rate of < 1%,
major error (MaE) rate of <5%, and a total error rate of <20%
were considered acceptable.
Results: Percentages of susceptible, intermediate, and
resistant isolates determined by the broth microdilution
method (disk diffusion method) are 81.7% (88.3%), 12.0%
(8.9%), and 6.3% (2.8%), respectively. VME, MaE, minor error,
and total error rates were 0.5% (2/393), 8.9% (35/393),
37.4% (147/393), and 46.8% (184/393), respectively.
Conclusion: Comparison with the broth microdilution
method for tigecycline against A. baumannii, the disk dif-
fusion method tends to have a high false-susceptibility rate
and have an unacceptable high VME.
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Background: The Tigecycline In-Vitro Surveillance in Tai-
wan (TIST), initiated in 2006, is a nationwide surveillance
program designed to monitor longitudinally the in vitro
activities of tigecycline against commonly encountered
resistant bacteria in Taiwan. This study aims to compare the
in vitro activities of tigecycline against clinical isolates of
Gram-negative bacteria by using two susceptibility methods.
Methods: A total of 1207 isolates of Gram-negative bacte-
ria were collected from various sources of patients treated
at 20 teaching hospitals. Minimum inhibitory concentrations
(MICs) for tigecycline of these isolates were determined by
the broth microdilution methods according the guidelines
described by Clinical and Laboratory Standards Institute
(CLSI) and the E test as manufacturer’s description. The
results for Enterobacteriaceae and A. baumannii were inter-
preted by the MIC criteria provided by U.S. FDA tigecycline
susceptibility breakpoints listed for Enterobacteriaceae (S,
≤2g/mL; I, 4g/mL; R, ≥8g/mL). Agreement (±1 log2
dilution) and error analysis of results generated by two
methods were also evaluated.
Results:Susceptibility rate (agreement of two methods)
for tigecycline was 99.6% (89.1%) for E. coli, 98.5% (72.4%)
for K. pneumoiae, 73.3% (86.6%) for P. mirabilis, 81.7%
(75.6%) for A. baumannii, and NA (89.1%) for S. maltophilia.
Very major error (0.5%) was found only for A. baumannii
isolates.
Conclusion: About 20% of A. baumannii isolates in Tai-
wan were resistant to tigecycline. The agreement between
the results obtained for tigecycline was limited (<80% agree-
ment) for ESBL-K. pneumoniae and A. baumannii.
doi:10.1016/j.ijid.2008.05.1069
